Navigation Links
Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
Date:2/21/2012

SAN DIEGO, Feb. 21, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Citi 2012 Global Health Care Conference in New York.   

The live presentation takes place on Wednesday, February 29 at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
2. Neurocrine Biosciences Reports Third Quarter 2011 Results
3. Neurocrine Biosciences Reports Second Quarter 2011 Results
4. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
5. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
6. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
7. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
8. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
9. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
10. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
11. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2019)... , ... November 06, 2019 , ... ... through off-the-record collaboration and dialogue, today announces its East/West CEO conference ... in San Francisco. , Kicking off the week of the J.P. ...
(Date:11/2/2019)... ... 31, 2019 , ... Join Patrick Raber, PhD, Manager, Research ... on Friday, November 15, 2019 at 1pm EST to learn about immunoSEQ ... T-cell receptors (TCRs) and B-cell receptors (BCRs), has been widely utilized to understand ...
(Date:10/29/2019)... ... October 29, 2019 , ... Modality Solutions, ... and cold chain validation workshop at the Biomanufacturing World Summit (BMWS19) Conference, November ... , The Biomanufacturing World Summit brings together pharmaceutical executives, cutting-edge technology ...
(Date:10/22/2019)... ... October 22, 2019 , ... Enplug , ... Mass Notification System into its digital signage platform. The collaboration brings one of ... possible for users to leverage their existing digital signage networks to quickly disseminate ...
Breaking Biology Technology:
(Date:11/12/2019)... , ... November 12, 2019 , ... ... air and water purifiers, announced today that distributors voted their patented automatic and ... MEGATRON ® water purifiers. , The most frequent maintenance task required of an ...
(Date:11/9/2019)... THURMONT, Md. (PRWEB) , ... ... ... merged with Alizée Pathology to form the leading provider of specialized histology, ... contract research industries. StageBio was recently created by the mergers of Histo-Scientific ...
(Date:11/6/2019)... ... November 06, 2019 , ... In October, Massachusetts stem ... to patients about a poorly disclosed deficiency in stem cell treatments. Throughout ... of the treating stem cells. This problem affects all patients receiving stem ...
Breaking Biology News(10 mins):